Genetic basis of tumorigenesis in NF1 malignant peripheral nerve sheath tumors

Frontiers in Bioscience

Volumn 16, Issue 3, 2011, Pages 937-951

  Upadhyaya, Meena ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Biomarkers; Genetics; Malignant peripheral nerve sheath tumor; Neurofibromatosis type1; NF1 somatic mutations; Prognostic markers; Review; Therapeutics

Indexed keywords

NEUROFIBROMIN;

ANIMAL; CANCER STEM CELL; COPY NUMBER VARIATION; DISEASE MODEL; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; MOUSE; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION PROFILING; HUMANS; MAGNETIC RESONANCE IMAGING; MICE; NEOPLASTIC STEM CELLS; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1;

EID: 79955004750     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3727     Document Type: Article

References (106)

1. M. Upadhyaya, D. Cooper:. In: Upadhyaya M, Cooper D (Eds). Neurofibromatosis type 1: from genotype to phenotype. Oxford: BIOS Scientific, 65-87. (1998)
2. E. Bennett, N. Thomas and M. Upadhyaya:Neurofibromatosis type-1: It association with the Ras/MAPK pathway syndromes. J PaeditrNeurol, 7, 1-5(2009)
3. H. Brems, E. Beert, T. de Ravel and E. Legius: Mechanisms in the pathogenesis of malignant tumors in neurofibromatosis type 1. Lancet Oncol, 10(5), 508-15 (2009)
4. T. Tucker, P. Wolkenstein, J. Revuz, J. Zeller and J. Friedman:Associationbetween benign and malignant peripheral nerve sheath tumors in NF1 Neurology, 65(2), 205-11 (2005) (Pubitemid 41022362)
5. R. Ferner and D. Gutmann: International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res, 62(5), 1573-7 (2002)
6. B. Ducatman, B. Scheithauer, D. Piepgras, H. Reiman and D. Ilstrup:Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120cases.Cancer, 57(10), 2006-21 (1986) (Pubitemid 16113778)
7. D. Evans, M. Baser, J. McGaughran, S. Sharif, E. Howard and A. Moran: Malignant peripheral nerve sheath tumors in neurofibromatosis 1.J Med Genet, 39(5), 311-4 (2002) (Pubitemid 34526349)
8. S. Grobmyer, J. Reith, A. Shahlaee, C. Bush and S. Hochwald:Malignant peripheral nerve sheath tumor: Molecular pathogenesis and current management considerations.J Surg Oncol, 97(4) (2008)
9. D. Ellison, J. Corredor-Buchmann, D. Parham and R. Jackson: Malignanttriton tumor presenting as a rectal mass in an 11-month-old. Pediatr Dev Pathol, 8(2), 235-9 (2005) (Pubitemid 40895703)
10. D. Cashen, R. Parisien, K. Raskin, F. Hornicek, M. Gebhardt and H. Mankin :Survival data for patients with malignant schwannoma. Clin Orthop Relat Re(426), 69-73 (2004) (Pubitemid 39167110)
11. M. Anghileri, R. Miceli, M. Fiore, L. Mariani, A. Ferrari, C. Mussi, L. LozzaP. Collini, P. Olmi, P. Casali, S. Pilotti and A. Gronchi: Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution.Cancer, 107(5), 1065-74 (2006) (Pubitemid 44291156)
12. T. De Raedt, H. Brems, P. Wolkenstein, D. Vidaud, S. Pilotti, F. Perrone, V. Mautner, S. Frahm, R. Sciot and E. Legius: Elevated risk for MPNST inNF1 microdeletion patients. Am J Hum Genet, 72(5), 1288-92 (2003) (Pubitemid 36530016)
13. R. Ferner, S. Huson, N. Thomas, C. Moss, H. Willshaw, D. Evans, M. Upadhyaya, R. Towers, M. Gleeson, C. Steiger and A. Kirby: Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet, 44(2), 81-8 (2007)
14. W. Brenner, R.Friedrich, K. Gawad, C. Hagel, A. von Deimling, M. de Wit, R. Buchert, M. Clausen and V. Mautner: Prognostic relevance of FDG PET inpatients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumors. Eur J Nuc Med Mol Imaging, 33(4), pages (2006)
15. V. Warbey, R. Ferner, J. Dunn, E. Calonje and M. O'Doherty: [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumors in neurofibromatosis type-1.Eur J Nucl Med Molimaging, 36(5), 751-7 (2009)
16. V. Mautner, F. Asuagbor, E. Dombi, C. Fünsterer, L. Kluwe, R. Wenzel, B.Widemann and J. Friedman: Assessment of benign tumor burden by hole-body MRI in patients with neurofibromatosis 1. Neuro Oncol, 10(4), 593-8 (2008)
17. D. Reuss and A. von Deimling: Biomarkers for malignant peripheral nerve sheath tumors (MPNST).Exp Opin Med Diagnosis, 2: 801-811 (2008)
18. J. Costa, R. Wesley, E. Glatstein and S. Rosenberg:The grading of soft tissue sarcomas.Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer, 53(3), 530-41 (1984) (Pubitemid 14182732)
19. M. Trojani, G. Contesso, J. Coindre, J. Rouesse, N. Bui, A. de Mascarel, J. Goussot, M. David, F. Bonichon and C. Lagarde: Soft-tissue sarcomas of adults; a study of pathological prognostic variables and definition of a histopathological grading system.Int J Cancer, 33(1), 37-42 (1984) (Pubitemid 14223231)
20. Stasik and O. Tawfik:Malignant peripheral nerve sheath tumor with rhabdomyosarcomatous differentiation (malignant triton tumor). Arch PatholLab Med, 130(12), 1878-81 (2006) (Pubitemid 44906971)
21. G. Spurlock, S. Knight, N. Thomas, T. Kiehl, A. Guha and M. Upadhyaya: Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: a correlation between histopathological, clinical and molecular findings.J Cancer Res Clin Oncol (2010 - in press)
22. M. Upadhyaya. Neurofibromatosis type-1: diagnosis and recent advances. Exp Opin Med Diagn ,4(4), 307-322, (2010)
23. S Welti, I D'angelo, Scheffzek: Structure and function of neurofibromin. InKaufmann D(ed): Neurofibromatoses. Monogr Hum Genet. Basel,Karger 16, 46-62 , (2008)
24. C. Johannessen, E. Reczek, M. James, H. Brems, E. Legius and K. Cichowski: The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci USA, 102(24), 8573-8 (2005) (Pubitemid 40862777)
25. D. Katz, A. Lazar and D. Lev: Malignant peripheral nerve sheath tumor (MPNST): the clinical implications of cellular signalling pathways. Exp ReMol Med, 11, e30 (2009)
26. G. Skuse, B. Kosciolek and P. Rowley:Molecular genetic analysis of tumors in von Recklinghausen neurofibromatosis: loss of heterozygosity for chromosome 17.Genes Chrom Cancer, 1(1), 36-41(1989) (Pubitemid 20093337)
27. T. Glover, C. Stein, E. Legius, L. Andersen, A. Brereton and S. Johnson: Molecular and cytogenetic analysis of tumors in von Recklinghausen neurofibromatosis.Genes Chrom Cancer, 3(1), 62-70 (1991)
28. Legius, D. Marchuk, F. Collins and T. Glover:Somatic deletion of the neurofibromatosis type-1 gene in a neurofibrosarcoma supports a tumor suppressor gene hypothesis.Nat Genet, 3(2), 122-6 (1993) (Pubitemid 23079793)
29. S. Rasmussen, J. Overman, S. Thomson, S. Colman, C. Abernathy, R. Trimpert, R. Moose, G. Virdi, K. Roux, M. Bauer, A. Rojiani, B. Maria, D.Muir and M. Wallace:Chromosome 17 loss-of-heterozygosity studies inbenign and malignant tumors in neurofibromatosis type-1. Genes Chrom Cancer, 28(4), 425-31 (2000) (Pubitemid 30451795)
30. A. John, M. Ruggieri, R. Ferner and M. Upadhyaya: A search forevidence of somatic mutations in the NF1 gene.J Med Genet, 37(1), 44-9 (2000) (Pubitemid 30245874)
31. A. Perry, K. Roth, R. Banerjee, C. Fuller and D. Gutmann:NF1 deletionin S-100 protein-positive and negative cells of both sporadic and neurofibromatosis 1 (NF1)-associated plexiform neurofibromas and malignant peripheral nerve sheath tumors.Am J Pathol, 159(1), 57-6 (2001)
32. T. Basu, D. Gutmann, J. Fletcher, T. Glover, F. Collins and J. Downward: Aberrant regulation of ras proteins in malignant tumor cells from type-1 neurofibromatosis patients. Nature, 356(6371), 713-5 (1992)
33. J. DeClue, A. Papageorge, J. Fletcher, S. Diehl, N. Ratner, W. Vass and D. Lowy:Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell, 69(2), 265-73 (1992)
34. A. Guha, N. Lau, I. Huvar, D. Gutmann, J. Provias, T. Pawson and G. Boss: Ras-GTP levels are elevated in human NF1 peripheral nerve tumors.Oncogene, 12(3), 507-13 (1996) (Pubitemid 26059644)
35. E. Serra, T. Rosenbaum, U. Winner, R. Aledo, E. Ars, X. Estivill, H. Lenardand C. Lázaro: Schwann cells harbor the somatic NF1 mutation in neurofibromas: evidence of two different Schwann cell subpopulations.Hum Mol Genet, 9(20), 3055-64 (2000) (Pubitemid 32000779)
36. N. Joseph, J. Mosher, J. Buchstaller, P. Snider, P. McKeever, M. Lim, S. Conway, L. Parada, Y. Zhu and S. Morrison:The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. Cancer Cell, 13(2), 129-40 (2008) (Pubitemid 351163162)
37. Y. Zhu, P. Ghosh, P. Charnay, D. Burns and L. Parada: Neurofibromas in NF1: Schwann cell origin and role of tumor environment.Science, 296(5569), 920-2 (2002) (Pubitemid 34464899)
38. F. Yang, D. Ingram, S. Chen, Y. Zhu, J. Yuan, X. Li, X. Yang, S. Knowles, W. Horn, Y. Li, S. Zhang, Y. Yang, S. Vakili, M. Yu, D. Burns, K. Robertson, G. Hutchins, L. Parada and D. Clapp:Nf1-dependent tumors require amicroenvironment containing Nf1+/- and c-kit-dependent bone marrow.Cell, 135(3), 437-48 (2008)
39. M. Upadhyaya, L. Kluwe, G. Spurlock, B. Monem, E. Majounie, K. Mantripragada, M. Ruggieri, N. Chuzhanova, D. Evans, R. Ferner, N. Thomas, A. Guha and V. Mautner:Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNST). Hum Mutat, 29(1), 74-82 (2008)
40. I. Bottillo, T. Ahlquist, H. Brekke, S. Danielsen, E. van den Berg, F. Mertens, R. Lothe and B. Dallapiccola:Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumors.J Pathol, 217(5), 693-701 (2009)
41. M. Upadhyaya, S. Han, C. Consoli, E. Majounie, M. Horan, N. Thomas, C. Potts, S. Griffiths, M. Ruggieri, A. von Deimling and D. Cooper:Characterization of the somatic mutational spectrum of the neurofibromatosis type-1 (NF1) gene in neurofibromatosis patients with benign and malignant tumors.Hum Mutat, 23(2), 134-46 (2004) (Pubitemid 38200604)
42. M. Upadhyaya, G. Spurlock, B. Monem, N. Thomas, R. Friedrich, L. Kluwe and V. Mautner: Germline and somatic NF1 gene mutations in plexiform neurofibromas.Hum Mutat, 29(8), E103-E111 (2008)
43. H Kehrer-Sawatzki: Structure of NF1 region and mechanisms underlying gross NF1 deletions.In:Kaufmann D(ed): Neurofibromatoses. Monog Hum Genet. Basel,Karger 16, 89-102 , (2008)
44. G. Nielsen, A. Stemmer-Rachamimov, Y. Ino, M. Moller, A. Rosenberg and D. Louis:Malignant transformation of neurofibromas in neurofibromatosisis associated with CDKN2A/p16 inactivation.Am J Pathol, 155(6), 1879-84, (1999)
45. F. Perrone, S. Tabano, F. Colombo, G. Dagrada, S. Birindelli, A. Gronchi, M. Colecchia, M. Pierotti and S. Pilotti: p15INK4b, p14ARF, and p16INK4a inactivation in sporadic and neurofibromatosis type-1-related malignant peripheral nerve sheath tumors. Clin Cancer Res, 9(11), 4132-8, (2003) (Pubitemid 37204030)
46. S. Frahm, V. Mautner, H. Brems, E. Legius, M. Debiec-Rychter, R. Friedrich,W. Knöfel, M. Peiper and L. Kluwe:Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type-1 patients. Neurobiol Dis, 16(1), 85-91,(2004) (Pubitemid 38569799)
47. T. Agesen, V. Flørenes, W. Molenaar, G. Lind, J. Berner, B. Plaat, R. Komdeur, O. Myklebost, E. van den Berg and R. Lothe:Expression patternsof cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol, 64(1), 74-81 (2005) (Pubitemid 40189481)
48. M. Sabah, R. Cummins, M. Leader and E. Kay:Loss of p16 (INK4A) expression is associated with allelic imbalance/loss of heterozygosity of chromosome 9p21 in microdissected malignant peripheral nerve sheath tumors.Appl Immunohistochem Mol Morphol, 14(1), 97-102 (2006)
49. R. Skotheim, A. Kallioniemi, B. Bjerkhagen, F. Mertens, H. Brekke, O. Monni, S. Mousses, N. Mandahl, G. Soeter, J. Nesland, S. Smeland, O. Kallioniemi and R. Lothe:Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol, 21(24), 4586-91 (2003) (Pubitemid 46594031)
50. E. Legius, H. Dierick, R. Wu, B. Hall, P. Marynen, J. Cassiman and T. Glover: TP53 mutations are frequent in malignant NF1 tumors. Genes Chrom Cancer, 10(4), 250-5 (1994) (Pubitemid 24238432)
51. K. Cichowski, T. Shih, E. Schmitt, S. Santiago, K. Reilly, M. McLaughlin, R. Bronson and T. Jacks:Mouse models of tumor development in neurofibromatosis type-1. Science, 286(5447), 2172-6 (1999) (Pubitemid 129516295)
52. K. Vogel, L. Klesse, S. Velasco-Miguel, K. Meyers, E. Rushing and L. Parada: Mouse tumor model for neurofibromatosis type 1. Science, 286(5447), 2176-9 (1999)
53. H. Kourea, I. Orlow, B. Scheithauer, C. Cordon-Cardo and J. Woodruff: Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas. Am J Pathol, 155(6), 1855-60 (1999)
54. H. Schmidt, H. Taubert, A. Meye, P. Würl, M. Bache, F. Bartel, H. Holzhausen and R. Hinze: Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease. Cancer Lett, 155(2), 181-90 (2000) (Pubitemid 30259133)
55. T. Koga, H. Iwasaki, M. Ishiguro, A. Matsuzaki and M. Kikuchi:Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumors detected by comparative genomic hybridization analysis.J Pathol, 197(1), 98-107 (2002) (Pubitemid 34450169)
56. D. Frank, B. Gunawan, M. Holtrup and L. Füzesi:Cytogenetic characterization of three malignant peripheral nerve sheath tumors. Cancer Genet Cytogenet, 144(1), 18-22 (2003) (Pubitemid 38367448)
57. R. Lothe, R. Karhu, N. Mandahl, F. Mertens, G. Saeter, S. Heim, A. Borresen-Dale and O. Kallioniemi: Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res, 56(20), 4778-81 (1996) (Pubitemid 26338084)
58. R. J. Bridge, J. Bridge, J. Neff, S. Naumann, P. Althof and L. Bruch: Recurrent chromosomal imbalances and structurally abnormal breakpoints within complex karyotypes of malignant peripheral nerve sheath tumor and malignant triton tumor: a cytogenetic and molecular cytogenetic study. J Clin Pathol, 57(11), 1172-8 (2004) (Pubitemid 39486524)
59. K. Mantripragada, G. Spurlock, L. Kluwe, N. Chuzhanova, R. Ferner, I.Frayling,JJ. Dumanski, A. Guha, V. Mautner and M. Upadhyaya: High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res, 14(4), 1015 24 (2008) (Pubitemid 351302546)
60. K. Mantripragada, T. de Ståhl, C. Patridge, U. Menzel, R. Andersson, N. Chuzhanova, L. Kluwe, A. Guha, V. Mautner, J. Dumanski and M. Upadhyaya:Genome-wide high-resolution analysis of DNA copy number alterations in NF1-associated malignant peripheral nerve sheath tumors using a 32K BAC microarray.Genes Chrom Cancer, 48(10), 897-907 (2009)
61. N. Holtkamp, A. Okuducu, J. Mucha, A. Afanasieva, C. Hartmann, I. Atallah, L. Estevez-Schwarz, C. Mawrin, R. Friedrich, V. Mautner and A. von Deimling: Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity. Carcinogenesis, 27(3), 664-71 (2006) (Pubitemid 43372895)
62. K. Karube, K. Nabeshima, M. Ishiguro, M. Harada and H. Iwasaki: cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumors.J Clin Pathol, 59(2), 160-5 (2006) (Pubitemid 43235581)
63. C. Storlazzi, H. Brekke, N. Mandahl, O. Brosjö, S. Smeland, R. Lothe and F.Mertens: Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumors.J Pathol, 209(4), 492-500 (2006) (Pubitemid 44194564)
64. S. Kresse, M. Skårn, H. Ohnstad, H. Namløs, B. Bjerkehagen, O. Myklebost and L. Meza-Zepeda:DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH. Mol Cancer, 7, 48 (2008)
65. M. Adamowicz, B. Radlwimmer, R. Rieker, D. Mertens, M. Schwarzbach, P.Schraml, A. Benner, P. Lichter, G. Mechtersheimer and S. Joos:Frequent amplifications and abundant expression of TRIO, NKD2, and IRX2 in soft tissue sarcomas. Genes Chrom Cancer, 45(9), 829-38 (2006) (Pubitemid 44182441)
66. P. Lévy, D. Vidaud, K. Leroy, I. Laurendeau, J. Wechsler, G. Bolasco, B. Parfait, P. Wolkenstein, M. Vidaud and I. Bièche: Molecular profiling ofmalignant peripheral nerve sheath tumors associated with neurofibromatosis type-1, based on large-scale real-time RT-PCR.Mol Cancer, 3, 20 (2004)
67. L. Angelov, B. Salhia, L. Roncari, G. McMahon and A. Guha: Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factorreceptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res, 59(21), 5536-41 (1999) (Pubitemid 29526470)
68. O. Kranenburg, M. Gebbink and E. Voest:Stimulation of angiogenesis by Ras proteins. Biochim Biophys Acta, 1654(1), 23-37 (2004) (Pubitemid 38230929)
69. S. Miller, F. Rangwala, J. Williams, P. Ackerman, S. Kong, A. Jegga, S.Kaiser,B. Aronow, S. Frahm, L. Kluwe, V. Mautner, M. Upadhyaya, D. Muir, M. Wallace, J. Hagen, D. Quelle, M. Watson, A. Perry, D. Gutmann and N. Ratner: Large-scale molecular comparison of human Schwann cells to malignantperipheral nerve sheath tumor cell lines and tissues.Cancer Res, 66(5), 2584-91 (2006)
70. S. Miller, W. Jessen, T. Mehta, A. Hardiman, E. Sites, S. Kaiser, A. Jegga, H. Li, M. Upadhyaya, M. Giovannini, D. Muir, M. Wallace, E. Lopez, E. Serra, G. Nielsen, C. Lazaro, A. Stemmer-Rachamimov, G. Page, B. Aronow and N. Ratner:Integrative genomic analyses of neurofibromatosis tumors identify SOX9 as a biomarker and survival gene.EMBO Mol Med, 1(4), 236-48 (2009)
71. K. Shintani, A. Matsumine, K. Kusuzaki, T. Matsubara, H. Satonaka, T.Wakabayashi, Y. Hoki and A. Uchida: Expression of hypoxia-inducible factor(HIF)-1alpha as a biomarker of outcome in soft-tissue sarcomas. Virchows Arch, 449(6), 673-81 (2006) (Pubitemid 44832639)
72. Bodempudi, F. Yamoutpoor, W. Pan, A. Dudek, T. Esfandyari, M. Piedra, D.Babovick-Vuksanovic, R. Woo, V. Mautner, L. Kluwe, D. Clapp, G. De Vries, S. Thomas, A. Kurtz, L. Parada and F. Farassati:Ral overactivation in malignant peripheral nerve sheath tumors. Mol Cell Biol, 29(14), 3964-74 (2009)
73. K. Mantripragada, M. Caley, P. Stephens, C. Jones, L. Kluwe, A. Guha, V. Mautner and M. Upadhyaya:Telomerase activity is a biomarker for highgrade malignant peripheral nerve sheath tumors in neurofibromatosis type-1 individuals. Genes Chrom Cancer, 47(3), 238-46 (2008) (Pubitemid 351162854)
74. X. Yan, M. Takahara, L. Dugu, L. Xie, C. Gondo, M. Endo, Y. Oda, TNakahara, H. Uchi, S. Takeuchi, Y. Tu, Y. Moroi and M. Furue: Expressionof cathepsin K in neurofibromatosis 1-associated cutaneous malignant peripheral nerve sheath tumors and neurofibromas.J Dermatol Sci, 58(3), 227-9 (2010)
75. S. Miller, Z. Lan, A. Hardiman, J. Wu, J. Kordich, D. Patmore, R. Hegde, T. Cripe, J. Cancelas, M. Collins and N. Ratner: Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis. Oncogene, 29(3), 368-79 (2010)
76. L. Lim, N. Lau, P. Garrett-Engele, A. Grimson, J. Schelter, J. Castle, D. Bartel, P. Linsley and J. Johnson:Microarray analysis shows that some microRNA down-regulate large numbers of target mRNAs. Nature, 433(7027), 769-73 (2005) (Pubitemid 40292988)
77. H. Wu and Y. Mo: Targeting miR-205 in breast cancer. Expert Opin Ther Targets, 13(12), 1439-48 (2009)
78. J. Weiler, J. Hunziker and J. Hall:Anti-miRNA oligonucleotides (AMOs): Ammunition to target miRNAs implicated in human disease?Gene Ther, 13(6), 496-502 (2006)
79. S. Subramanian, W. Lui, C. Lee, I. Espinosa, T. Nielsen, M. Heinrich, C. Corless, A. Fire and M. van de Rijn:MicroRNA expression signature of human sarcomas. Oncogene, 27(14), 2015-26 (2008) (Pubitemid 351442735)
80. S. Subramanian, V. Thayanithy, R. West, C. Lee, A. Beck, S. Zhu, E. Downs-Kelly, K. Montgomery, J. Goldblum, P. Hogendoorn, C. Corless, A. Oliveira,S. Dry, T. Nielsen, B. Rubin, J. Fletcher, C. Fletcher and M. van de Rijn:Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumors. J Pathol 220(1), 58-70 (2010)
81. G. Chai, N. Liu, J. Ma, H. Li, J. Oblinger, A. Prahalad, M. Gong, L. Chang, M.Wallace, D. Muir, A. Guha, R. Phipps, J. Hock and X. Yu:MicroRNA-10b regulates tumorigenesis in neurofibromatosis type 1. Cancer Sci May 12. [Epub ahead of print] (2010)
82. M. Wicha: Targeting breast cancer stem cells. Breast, 18 Suppl 3, S56-8 (2009)
83. A. Clark: The stem cell identity of testicular cancer. Stem Cell Rev, 3(1), 49-59(2007) (Pubitemid 47472811)
84. . G. Hesselager and E. Holland: Using mice to decipher the molecular genetics of brain tumors. Neurosurgery, 53(3), 685-95 (2003) (Pubitemid 37055947)
85. Carroll and N. Ratner: How does the Schwann cell lineage form tumors in NF1? Glia, 56(14), 1590-605 (2008)
86. C. Gregorian, J. Nakashima, S. Dry, P. Nghiemphu, K. Smith, Y. Ao, J. Dang, G. Lawson, I. Mellinghoff, P. Mischel, M. Phelps, L. Parada, X. Liu, M. Sofroniew, F. Eilber and H. Wu:PTEN dosage is essential for neurofibroma development and malignant transformation. Proc Natl Acad Sci USA, 106(46),19479-84 (2009)
87. C. Mawrin: Critical role of PTEN for development and progression of nerve sheath tumors in neurofibromatosis type-1. Future Oncol, 6(4), 499-501 (2010)
88. C. Johannessen, B. Johnson, S. Williams, A. Chan, E. Reczek, R. Lynch, M. Rioth, A. McClatchey, S. Ryeom and K. Cichowski:TORC1 is essential forNF1-associated malignancies.Curr Biol, 18(1), 56-62 (2008)
89. C. Johansson, Y. Mahller, M. Collins, M. Kim, T. Nobukuni, J. Perentesis, T.Cripe, H. Lane, S. Kozma, G. Thomas and N. Ratner:Effective in vivotargeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther, 7(5), 1237-45 (2008)
90. P. Bhola, S. Banerjee, J. Mukherjee, A. Balasubramanium, V. Arun, Z. Karim, K. Burrell, S. Croul, D. Gutmann and A. Guha: Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int J Cancer, 126(2), 563-71 (2010)
91. Guba. P. von Breitenbuch, M. Steinbauer, G. Koehl, S. Flegel, M. Hornung, C. Bruns, C. Zuelke, S. Farkas, M. Anthuber, K. Jauch and E. Geissler: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med, 8(2), 128-35 (2002) (Pubitemid 34155123)
92. J. Dilworth, J. Kraniak, J. Wojtkowiak, R. Gibbs, R. Borch, M. Tainsky, J. Reiners and R. Mattingly: Molecular targets for emerging anti-tumor therapies for neurofibromatosis type-1.Biochem Pharmacol, 72(11), 1485-92 (2006) (Pubitemid 44666729)
93. N. Holtkamp, E. Malzer, J. Zietsch, A. Okuducu, J. Mucha, C. Mawrin, V. Mautner, H. Schildhaus and A. von Deimling:EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol, 10(6), 946-57 (2008)
94. M. Aoki, K. Nabeshima, K. Koga, M. Hamasaki, J. Suzumiya, K. Tamura and H. Iwasaki:Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB. Lab Invest, 87(8), 767-79 (2007) (Pubitemid 47077256)
95. G. Ambrosini, H. Cheema, S. Seelman, A. Teed, E. Sambol, S. Singer and G. Schwartz:Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. Mol Cancer Ther, 7(4), 890-6 (2008) (Pubitemid 351551042)
96. Wojtkowiak. F, Fouad, D. LaLonde, M. Kleinman, R. Gibbs, J. J. Reiners, R. Borch and R. Mattingly: Induction of apoptosis in neurofibromatosis type-1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. J Pharmacol Exp Ther, 326(1), 1-11 (2008) (Pubitemid 351872120)
97. T. Turbyville, D. Gürsel, R. Tuskan, J. Walrath, C. Lipschultz, S. Lockett, D. Wiemer, J. Beutler and K. Reilly:Schweinfurthin A selectively inhibit proliferation and Rho signaling in glioma and neurofibromatosis type-1 tumor cells in a NF1-GRD-dependent manner. Mol Cancer Ther, 9(5), 1234-43 (2010)
98. B. Widemann: Current status of sporadic and neurofibromatosis type-1- associated malignant peripheral nerve sheath tumors. Curr Oncol Rep, 11(4), 322-8 (2009)
99. K. Albritton, C. Rankin, C. Coffin, N. Ratner, G. Budd, S. Schuetze, R. Randall, J. Declue, E. Borden: Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST).J Clin Oncol 24:9518 (2006).
100. R. Maki, D. D'Adamo, M. Keohan, M. Saulle, S. Schuetze, S. Undevia, M. Livingston, M. Cooney, M. Hensley, M. Mita, C. Takimoto, A. Kraft, A. EliasB. Brockstein, N. Blachère, M. Edgar, L. Schwartz, L. Qin, C. Antonescu and G. Schwartz:Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.J Clin Oncol, 27(19), 3133-40 (2009)
101. J. Kissil, J. Blakeley, R. Ferner, S. Huson, M. Kalamarides, V. Mautner, F. McCormick, H. Morrison, R. Packer, V. Ramesh, N. Ratner, K. Rauen, D.Stevenson, K. Hunter-Schaedle and K. North:What's new in neurofibromatosis? Proceedings from the 2009 NF Conference: new frontiers. Am J Med Genet A, 152A(2), 269-83 (2010)
102. C. Zou, K. Smith, Q. Zhu, J. Liu, I. McCutcheon, J. Slopis, F. Meric-Bernstam, Z. Peng, W. Bornmann, G. Mills, A. Lazar, R. Pollock and D. Lev:Dual targeting of AKT and mammalian target of rapamycin: A potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther, 8(2), 1157-8(2009)
103. D. Parsons, S. Jones, X. Zhang, J. Lin, R. Leary, P. Angenendt, P. Mankoo, H. Carter, I. Siu, G. Gallia, A. Olivi, R. McLendon, B. Rasheed, S. Keir, T. Nikolskaya, Y. Nikolsky, D. Busam, H. Tekleab, L. J. Diaz, J. Hartigan, D. Smith, R. Strausberg, S. Marie, S. Shinjo, H. Yan, G. Riggins, D. Bigner, R. Karchin, N. Papadopoulos, G. Parmigiani, B. Vogelstein, V. Velculescu and K Kinzler:An integrated genomic analysis of human glioblastoma multiformeScience, 321(5897), 1807-12 (2008)
104. L. Ding, G. Getz, D. Wheeler, E. Mardis, M. McLellan, K. Cibulskis, C.Sougnez, H. Greulich, D. Muzny, M. Morgan, L. Fulton, R. Fulton, Q. Zhang,M. Wendl, M. Lawrence, D. Larson, K. Chen, D. Dooling, A. Sabo, A. Hawes, H. Shen, S. Jhangiani, L. Lewis, O. Hall, Y. Zhu, T. Mathew, Y. Ren, J. Yao,S. Scherer, K. Clerc, G. Metcalf, B. Ng, A. Milosavljevic, M. Gonzalez-Garay, J. Osborne, R. Meyer, X. Shi, Y. Tang, D. Koboldt, L. Lin, R. Abbott, T.Miner, C. Pohl, G. Fewell, C. Haipek, H. Schmidt, B. Dunford-Shore, A. Kraja,S. Crosby, C. Sawyer, T. Vickery, S. Sander, J. Robinson, W. Winckler, J.Baldwin, L. Chirieac, A. Dutt, T. Fennell, M. Hanna, B. Johnson, R. Onofrio, R. Thomas, G. Tonon, B. Weir, X. Zhao, L. Ziaugra, M. Zody, T. Giordano, M. Orringer, J. Roth, M. Spitz, I. Wistuba, B. Ozenberger, P. Good, A. Chang, D.Beer, M. Watson, M. Ladanyi, S. Broderick, A. Yoshizawa, W. Travis, W. Pao, M. Province, G. Weinstock, H. Varmus, S. Gabriel, E. Lander, R. Gibbs, M.Meyerson and R. Wilson:Somatic mutations affect key pathways in lungadenocarcinoma.Nature, 455(7216), 1069-75 (2008)
105. N. Sangha, R. Wu, R. Kuick, S. Powers, D. Mu, D. Fiander, K. Yuen, H.Katabuchi, H. Tashiro, E. Fearon and K. Cho: Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.Neoplasia, 10(12), 1362-72, (2008)
106. C. Haferlach, F. Dicker, A. Kohlmann, S. Schindela, T. Weiss, W. Kern, S. Schnittger and T. Haferlach:AML with CBFB-MYH11 rearrangement demonstrate RAS pathway alterations in 92% of all cases including a high frequency of NF1 deletions.Leukemia, 24(5), 1065-9 (2010)